4D Molecular Therapeutics, Inc.
FDMT
NASDAQ·Healthcare·Biotechnology·Mkt cap $782.6M
$14.97
▲ +1.84%
P/E
-5.50
Mkt Cap
$782.6M
52-Wk Range
$6.47–$16.93
52-Week Range
$6.47 - $16.93
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 114.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AAV vector technology platform with enhanced tissue targeting capabilities
- Strategic partnerships with Roche, uniQure, and Cystic Fibrosis Foundation providing validation and resources
- Diversified pipeline across three therapeutic areas reducing single-program risk
- Clinical-stage validation with multiple Phase 1/2 trials demonstrating safety and efficacy signals
Bear Case
1 risk
- High volatility (beta 2.7). Larger-than-normal price swings expected.
Growth
Stable outlook
Advancement of clinical candidates toward Phase 2/3 trials and potential regulatory approvals
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+73.3% over 3m
Quality
Strong
High-growth business (500% revenue growth, 42% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying FDMT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
AUG 13, 2026
Reported EPS of -$1.04 vs -$1.02 consensus (-2.0% surprise). Revenue of $3.8M vs $3.6M expected (+4.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.0%
Revenue trend · last 8Q
—
+105%
-50%
+200%
+2900%
+8508900%
+21664%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.0K
$1.0K
$14.0K
$15.0K
$90.0K
$85.1M
$3.0M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Aug 13, 2026
vs Industry
How FDMT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related